Generic drug sponsors want US Food and Drug Administration help to salvage bioequivalence studies disrupted by the coronavirus pandemic, but a consultant warned the problem will not disappear after the outbreak is contained.
Michelle Ryder, principal consultant in the regulatory practice at Lachman Consultants, said the help is vital for the industry, because
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?